$38.96 -0.12 (-0.31%) Alnylam Pharmaceuticals Inc - NASDAQ

Jan. 20, 2017 | 04:00 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 38.96
Trade Time: Jan 20 04:00 PM Eastern Daylight Time
Change: -0.12 (-0.31%)
Prev Close: 39.08
Open: 39.12
Bid: 38.96
Ask: 38.97
  1. Large Cap Best And Worst Report - Tuesday, Jan. 17

    TalkMarkets | Jan. 17, 2017 | 09:16AM EST
  2. Large Cap Best & Worst Report - Tuesday, Jan. 3

    TalkMarkets | Jan. 3, 2017 | 08:05AM EST
  3. Market Reversal In Biotech But Healthcare Stocks Are Still Muddled

    TalkMarkets | Nov. 29, 2016 | 22:56PM EST
  4. Biotech Stocks Soar on Election Results, Gilead HBV Drug Approved

    TalkMarkets | Nov. 16, 2016 | 15:30PM EST
  5. Rayno Biobeat #3…Trump Biotech Rally Leads Market Up

    TalkMarkets | Nov. 9, 2016 | 23:23PM EST
  6. IPO Preview: Ra Pharmaceuticals

    TalkMarkets | Oct. 26, 2016 | 01:02AM EST
  7. Biotechnology Bear Market: Trends To Watch For A 2016 Q4 Rally

    TalkMarkets | Oct. 12, 2016 | 23:02PM EST
  8. Biotech Stock Roundup: Alnylam Slumps On Revusiran Update, TESARO Impresses At ESMO

    TalkMarkets | Oct. 12, 2016 | 11:14AM EST
  9. Battleground: Alnylam Plunges After Revusiran Pulled, But Some See Opportunity

    TalkMarkets | Oct. 6, 2016 | 19:50PM EST
  10. Morning Call For October 6, 2016

    TalkMarkets | Oct. 6, 2016 | 08:17AM EST
  11. Biotech Stocks Recovering From Last Week’s Free Fall

    TalkMarkets | Oct. 5, 2016 | 23:06PM EST
  12. Medicines Co. up on sale talk

    IBD | Jan. 20, 2016 | 18:40PM EST
  13. Medicines Company Spikes On Report Of Possible Sale

    IBD | Jan. 20, 2016 | 12:59PM EST
  14. Alnylam Pharmaceuticals Dips Lower After Company Announces 2016 Pipeline Goals Towards 'Alnylam 2020'

    Benzinga | Jan. 11, 2016 | 13:57PM EST
  15. Alnylam Reports Positive Phase 1 Study Results for Once-Monthly, Subcutaneous Fitusiran (ALN-AT3) in Patients with Hemophilia A and B

    Benzinga | Dec. 7, 2015 | 10:30AM EST
Trading Center